A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
Participants with no clinical history of atherosclerotic cardiovascular disease (ASCVD) and a 10-year ASCVD risk estimated as low
Participants who have not received any LLT in the 3 months prior to screening
You may not be if
Asian origin.
Statin intolerance
Uncontrolled severe hypertension
Uncontrolled type 2 diabetes mellitus
Inadequately treated hypothyroidism
Clareo Health | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
